Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 12 875 / https://doi.org/10.3332/ecancer.2018.875

Short Communication

Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series

Background: Regorafenib is a therapeutic alternative for patients with metastatic colorectal cancer (MCRC) resistant to conventional therapies. The reported toxicity is relevant and there is no data on Latin American patients. The objective was to evaluate the overall survival (OS), progression-free survival (PFS) and quality of life (QoL) in a prospective cohort of Latin American patients treated with an adjusted dose of regorafenib.

Methods: We prospectively recruited patients with MCRC that progressed to standard therapy. A dose escalation algorithm was used. OS, PFS, response rate and QoL were evaluated.

Results: We recruited 13 patients between June and November 2015. The median age was 60 years. Median OS was 8.6 months and median PFS was 2.2 months. The response rate was 8%. Grade 3–4 toxicities included grade 3 palmoplantar erythrodysesthesia in 23% and grade 3 fatigue in 12% of patients.

Conclusion: Regorafenib treatment is effective in Latin American patients with conventional therapy resistant MCRC.

Keywords: regorafenib, antiangiogenic, colorectal neoplasms, Latin America

Loading Article Metrics ... Please wait

Related articles

Conference Report: Highlights of the 16th St Gallen International Breast Cancer Conference, Vienna, Austria, 20–23 March 2019: personalised treatments for patients with early breast cancer

Abstract | Full Article | PDF Published: 24 Apr 2019 / https://doi.org/10.3332/ecancer.2019.924

Research: Breast lesions with atypia in percutaneous biopsies, managed with surgery in the last 10 years

Abstract | Full Article | PDF | Spanish Published: 11 Apr 2019 / https://doi.org/10.3332/ecancer.2019.923

Case Report: Primary cardiac angiosarcoma diagnosed in the first trimester of pregnancy

Abstract | Full Article | PDF Published: 09 Apr 2019 / https://doi.org/10.3332/ecancer.2019.922

Clinical Study: Assessing the tolerability and efficacy of first-line chemotherapy in elderly patients with metastatic HER2−ve breast cancer

Abstract | Full Article | PDF Published: 03 Apr 2019 / https://doi.org/10.3332/ecancer.2019.921

Policy: Precision oncology in Latin America: current situation, challenges and perspectives

Abstract | Full Article | PDF | Spanish Published: 03 Apr 2019 / https://doi.org/10.3332/ecancer.2019.920



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation